文献速递心律失常心力衰竭与心肌病

起搏器是否有影响?快慢综合征患者房颤消融后的长期结局

Does a Pacemaker Make a Difference? Long‐Term Outcomes Post‐AF Ablation in Tachy‐Brady Syndrome
RSS 订阅 · Journal of Cardiovascular Electrophysiology · 2025-10-17

该研究基于多中心ITHACA注册登记,回顾性分析2015至2021年接受房颤消融的快慢综合征(TBS)患者,按消融时是否已植入永久起搏器(PPM)分组。结果显示两组复合失败率无显著差异,但PPM组全因住院率更高,延迟植入PPM与更高失败率和更多住院相关,作者建议部分患者可考虑早期或同期植入PPM,但需更大规模前瞻性研究。

要点

  • 在房颤消融的TBS患者中,消融时已植入PPM与未植入PPM者的复合失败率无显著差异。
  • PPM组全因住院率显著高于无PPM组(85% vs 62%,p=0.01)。
  • 延迟植入PPM者12个月复合失败率更高(65% vs 42%,p=0.001),作者认为部分患者早期或同期植入PPM可能获益。

核心结论

  • 在因房颤接受消融的TBS患者中,复合失败率不因基线是否已植入PPM而异,但PPM组住院率更高,提示该组人群可能病情更重。
  • 延迟植入PPM与更高的消融失败率和更多住院相关,作者认为早期或同期植入PPM可能使部分患者获益,需更大规模前瞻性研究明确预测因素并优化管理。

研究设计与样本

  • 多中心ITHACA注册登记的回顾性分析,纳入2015至2021年五家Northwell Health中心接受房颤消融的患者。
  • 3440例接受房颤消融的患者中111例(3.2%)为TBS,54例(49%)在索引消融时已植入PPM。
  • 34例失访,余77例中位随访44.2个月;无PPM组中26例(46%)在消融后中位292天延迟植入PPM。

主要发现

  • 12个月复合失败率在PPM组与无PPM组分别为42%与40%(p=0.93),末次随访时分别为44%与47%(p=0.91)。
  • 全因住院率在PPM组显著高于无PPM组(85% vs 62%,p=0.01)。
  • 延迟植入PPM者12个月复合失败率高于无PPM者(65% vs 42%,p=0.001),末次随访时分别为73%与44%(p=0.056)。
  • 延迟植入PPM者与无PPM者再入院率分别为69%与54%(p=0.87)。
  • 末次随访时PPM组仍使用β受体阻滞剂者比例高于无PPM组(61% vs 35%,p=0.002),抗心律失常药物使用在各组均下降。

临床怎么用

  • 作者认为,对于接受房颤消融的TBS患者,延迟植入PPM与更高失败率和更多住院相关,早期或同期植入PPM可能使部分患者获益。
  • 作者指出需更大规模前瞻性研究明确预测因素并优化管理。

局限性

  • 原文为回顾性分析。
  • 34例患者失访。
  • 作者指出需更大规模前瞻性研究来明确预测因素并优化管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Introduction Tachy-brady syndrome (TBS), a subtype of sinus node dysfunction, is characterized by alternating bradyarrhythmia and supraventricular tachyarrhythmias. While catheter ablation (CA) for atrial fibrillation (AF) offers improved long-term outcomes, many patients with TBS undergo permanent pacemaker (PPM) implantation to manage symptomatic bradycardia or enable rate-control therapy. Data on long-term outcomes postablation, stratified by PPM status, are limited. Methods We conducted a retrospective analysis within the multicenter ITHACA registry, which includes patients who underwent AF ablation across five Northwell Health centers from 2015 to 2021. Patients with TBS were stratified by PPM status at index ablation. Primary outcomes were composite failure (AF recurrence with continued antiarrhythmic drug [AAD] use, cardioversion beyond the blanking period, or repeat ablation) beyond the 3-month blanking period at 12 months and last follow-up, and all-cause hospitalization. Secondary outcomes included beta-blocker and AAD use postablation. Comparisons were performed using Chi-square tests. Results Among 3,440 patients who underwent AF ablation, 111 (3.2%) had TBS; 54 (49%) had a PPM at index ablation. Thirty-four patients were lost to follow-up. Remaining 77 patients had a median follow-up of 44.2 months. Of those without a PPM at ablation, 26 (46%) required delayed PPM (median 292 days postablation). At 12 months, composite failure rates were similar between PPM and no-PPM groups (42% vs. 40%, p = 0.93) and remained comparable at last follow-up (44% vs. 47%, p = 0.91). Hospitalization was significantly higher in the PPM group compared to no-PPM (85% vs. 62%, p = 0.01). Subgroup analysis revealed that delayed PPM patients had higher failure at 12 months (65% vs. 42%, p = 0.001) and at last follow-up (73% vs. 44%, p = 0.056). Furthermore, there was numerically higher readmission between delayed PPM vs no PPM group (69% vs 54%, p = 0.87). More patients in the PPM group remained on beta-blockers at last follow-up (61% vs. 35%, p = 0.002), while AAD use declined across groups. Conclusion In TBS patients undergoing AF ablation, overall failure rates did not differ by initial PPM status, though there was a higher hospital readmission in PPM group, suggesting a potential sicker population. Furthermore, delayed PPM implantation was associated with higher failure and more hospitalizations, suggesting earlier or concurrent PPM may benefit selected patients. Larger prospective studies are needed to define predictors and optimize management.

来源:Journal of Cardiovascular Electrophysiology,查看原文。版权归原作者所有。

引用

  1. Journal of Cardiovascular Electrophysiology:Does a Pacemaker Make a Difference? Long‐Term Outcomes Post‐AF Ablation in Tachy‐Brady Syndrome

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。